Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Tumor G3”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Testing effectiveness (Phase 2)UnknownNCT03457844
What this trial is testing

Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor G3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 60
Testing effectiveness (Phase 2)Study completedNCT03980925
What this trial is testing

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595424
What this trial is testing

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Who this might be right for
Gastric Neuroendocrine CarcinomaIntestinal Neuroendocrine CarcinomaPancreatic Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research Group 67
Testing effectiveness (Phase 2)Study completedNCT02248012
What this trial is testing

Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

Who this might be right for
Neuroendocrine Carcinoma
Haukeland University Hospital 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05894486
What this trial is testing

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Peking University 40
Testing effectiveness (Phase 2)UnknownNCT03963193
What this trial is testing

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Who this might be right for
Gastrointestinal Neuroendocrine Tumor
Henan Cancer Hospital 112
Not applicableActive Not RecruitingNCT04804371
What this trial is testing

Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University Health Network, Toronto 40